SGS is pleased to announce the acquisition of proderm, the leading provider of advanced clinical testing solutions for cosmetics, personal care and medical products in Germany.
Founded in 1994, proderm is headquartered in Hamburg, with two additional locations in Germany, and serves clients in the consumer care and pharmaceutical industries around the globe. As a Clinical Research Organization (CRO) conducting clinical studies from initial consultation to final report, proderm demonstrated consistent growth during the fiscal year ending June 30, 2021, generating revenues of c. CHF 13 million. proderm employs nearly 140 highly skilled employees who will join SGS cosmetics and hygiene services’ unparalleled network of 45 laboratories and clinical testing sites across North America, Europe and Asia.
Frankie Ng, CEO of SGS, said: “This acquisition supports our strategic evolution by further aligning our global network more closely with the key TIC megatrends and customer demands of the Health & Nutrition industry. It significantly reinforces our leading global position in cosmetics and personal care testing, adding innovative capabilities, strong scientific expertise and enhances our strong reputation.”
Our Cosmetics and Hygiene Services
SGS is the world leader in cosmetics, detergent and hygiene testing with a unique network of more than 45 laboratories and clinical testing sites in North America, Europe and Asia. We offer turnkey and innovative solutions including analytical, microbiological and in vitro testing, clinical studies for safety and efficacy as well as regulatory services.
We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for quality and integrity. Our 96,000 employees operate a network of 2,600 offices and laboratories, working together to enable a better, safer and more interconnected world.